Understanding Differences in Pharmaceutical Products Based on Price Publication Status

Speaker(s)

Duteil E1, Rivière L2, Monnier R2, Le Dissez C3
1PASS, Bègles, 33, France, 2PASS, Bègles, France, 3PASS, Bois d'Arcy, 78, France

Presentation Documents

OBJECTIVES: The objective of this study was to evaluate the effect of Clinical Added Value (CAV) levels and labels on the price publication status (with or without price published).

METHODS: Opinions issued by the Transparency Committee between April 2021 and May 2024 were extracted from the HAS website. Only initial listings of products with an CAV rating were included. Generics and biosimilars were excluded. All products with published prices were included, as well as products without published prices that have been in negotiation for more than 90 days. A total of 141 indications (138 products), with 76 having published prices and 65 without. Descriptive statistical analyses were conducted to compare the mean negotiation durations between products with published prices and those without. Additionally, a Chi-square test was performed to explore differences in CAV label and level distributions between the two groups.

RESULTS: The mean negotiation duration for products with published prices was 275.00 days, whereas products without published prices had a significantly longer mean duration of 545.58 days.

The CAV level did not affect price publication status (similar frequencies and no statistically significant differences between the two groups (p = 0.462)). However, the Chi-square test for CAV label showed significant differences between the two groups (p = 0.009). Specifically, the “Same as” label exhibited notable discrepancies, with standardized residuals of -2.04 for products without published prices and 1.88 for those with published prices, suggesting that this category is more frequent among products with published prices.

CONCLUSIONS: The study highlights that, contrary to the CAV level, the CAV labels may significantly impact price publication status. The notable frequency of the “Same as” label among products with published prices suggests that this category may be associated with successful negotiation outcomes.

Code

HPR166

Topic

Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Approval & Labeling, Decision & Deliberative Processes, Pricing Policy & Schemes, Reimbursement & Access Policy

Disease

Drugs